Safety and efficacy of the levonorgestrel-releasing intrauterine system: recent insights

Levonorgestrel Intrauterine System for Contraception: An Expert Panel Consensus Statement

“…Although long-term efficacy data were limited, one of the studies suggested the effect is maintained through 4 years of device use. 21 The device was also found to be safe with no uterine perforations observed in randomized clinical trials and a large, controlled Europe-based, surveillance study on IUDs. Randomized controlled trial evidence highlighted a partial or complete expulsion rate for the device of <5%.…”

“…After contraception, one of the main indications of LNG-IUS is for the treatment of HMB, as it causes endometrial suppression, thereby reducing bleeding. 20,21 In a benefit-risk review of LNG-IUS in HMB by Kauntiz et al, LNG-IUS was found to be associated with greater menstrual blood loss (MBL) reduction compared with other treatment options, viz. oral contraceptives, tranexamic acid, and oral mefenamic acid.…”

“…It is also cost-effective and exerts a positive impact on the overall QoL, when compared with endometrial ablation and hysterectomy. 21 There is evidence that the device is beneficial in adenomyosisassociated HMB and dysmenorrhea. 22,23 A study was conducted to compare the effect of LNG-IUS and copper IUD on mensuration and dysmenorrhea.…”

LNG-IUS for helping a doctor during the most difficult period of women’s reproductive aging

“…Во многих исследованиях продемонстрированы последовательные данные об отсутствии клинически значимого влияния ЛНГ-ВМС на артериальное дав-ление, липидный профиль, уровень С-реактивного белка, являющегося важным маркером субклиниче-ского воспаления и повышения сердечно-сосуди-стого риска, углеводный обмен и чувствительность к инсулину [56][57][58]. Поэтому использование различ-ных форм эстрогенов в комбинации с ЛНГ-ВМС не сопровождается значимым влиянием на липидный профиль и другие маркеры сердечно-сосудистого риска в отличие от пероральных прогестагенов, на-пример, с глюкокортикоидным эффектом, как в слу-чае МПА.…”

Reproductive health information, behaviour and sexual education of adolescent girls in Hungary

“…can be dispelled by the Resolution of the Professional College of Obstetrics and Gynecology, Assisted Reproductive Section: Intrauterine contraception in nulliparous women (Major, 2014), and several other international studies as well. There are papers about the eligibility criteria for using the LARC method, the circumstances of IUD/ LNG-IUS insertion, about that routine prophylactic antibiotic treatment is not justified, but based on sexual history patients can be categorised and screening can be performed for sexually transmitted diseases (Arisi, et al, 2014;Caddy, et al, 2014;Diedrich, et al, 2017;Gemzell-Danielsson, et al, 2013;Pritt, et al, 2017;Sufrin, et al, 2012;WHO, 2015).…”